LENZ Therapeutics Valuation
| LENZ Stock | 12.88 0.09 0.69% |
At this time, the firm appears to be undervalued. LENZ Therapeutics secures a last-minute Real Value of USD22.19 per share. The latest price of the firm is USD12.88. Our model forecasts the value of LENZ Therapeutics from evaluating the firm fundamentals such as return on equity of -0.29, and Operating Margin of (1.51) % as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting LENZ Therapeutics' valuation include:
Price Book 2.0782 | Enterprise Value | Enterprise Value Ebitda (7.99) | Price Sales 23.0294 | Enterprise Value Revenue 11.5312 |
Undervalued
Today
Please note that LENZ Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of LENZ Therapeutics is based on 3 months time horizon. Increasing LENZ Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since LENZ Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of LENZ Stock. However, LENZ Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 12.88 | Real 22.19 | Target 51.29 | Hype 14.01 |
The intrinsic value of LENZ Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence LENZ Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of LENZ Therapeutics helps investors to forecast how LENZ stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of LENZ Therapeutics more accurately as focusing exclusively on LENZ Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use LENZ Therapeutics' intrinsic value based on its ongoing forecasts of LENZ Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against LENZ Therapeutics' closest peers.
LENZ Therapeutics Cash |
|
LENZ Therapeutics Total Value Analysis
LENZ Therapeutics is now estimated to have valuation of 201.8 M with market capitalization of 403.01 M, debt of 1.38 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the LENZ Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
201.8 M | 403.01 M | 1.38 M |
LENZ Therapeutics Asset Utilization
One of the ways to look at asset utilization of LENZ is to check how much profit was generated for every dollar of assets it reports. LENZ Therapeutics secures a negative usage of assets of -0.2 %, losing USD0.001952 for each dollar of assets held by the firm. Ineffective asset utilization conveys that the company is being less capable with each dollar of assets it secures. Strictly speaking, asset utilization of LENZ Therapeutics shows how unsuccessful it operates for each dollar spent on its assets.LENZ Therapeutics Profitability Analysis
Based on LENZ Therapeutics' profitability indicators, LENZ Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess LENZ Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2020-03-31 | Previous Quarter -14.9 M | Current Value -16.7 M | Quarterly Volatility 12.4 M |
For LENZ Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of LENZ Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well LENZ Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between LENZ Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of LENZ Therapeutics over time as well as its relative position and ranking within its peers.
LENZ Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of LENZ Therapeutics is estimated to be -0.6458 with future projections ranging from a low of -0.6848 to a high of -0.5875. LENZ Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -2.06. Please be aware that the consensus of earnings estimates for LENZ Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.LENZ Therapeutics Earnings Estimation Breakdown
The calculation of LENZ Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of LENZ Therapeutics is estimated to be -0.6458 with the future projection ranging from a low of -0.6848 to a high of -0.5875. Please be aware that this consensus of annual earnings estimates for LENZ Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.68 Lowest | Expected EPS | -0.59 Highest |
LENZ Therapeutics Earnings Projection Consensus
Suppose the current estimates of LENZ Therapeutics' value are higher than the current market price of the LENZ Therapeutics stock. In this case, investors may conclude that LENZ Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and LENZ Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 7 | 52.99% | -0.59 | -0.6458 | -2.06 |
LENZ Therapeutics Ownership Allocation
The majority of LENZ Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in LENZ Therapeutics to benefit from reduced commissions. Thus, institutional holders are subject to a different set of regulations than regular investors in LENZ Therapeutics. Please pay attention to any change in the institutional holdings of LENZ Therapeutics as this could imply that something significant has changed or is about to change at the company.LENZ Therapeutics Profitability Analysis
Net Loss for the year was (49.77 M) with profit before overhead, payroll, taxes, and interest of 17.5 M.LENZ Therapeutics Past Distributions to stockholders
About LENZ Therapeutics Valuation
Our relative valuation model uses a comparative analysis of LENZ Therapeutics. We calculate exposure to LENZ Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of LENZ Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -52.2 K | -49.6 K | |
| Pretax Profit Margin | (0.63) | (0.66) | |
| Operating Profit Margin | (0.63) | (0.66) | |
| Net Loss | (0.65) | (0.68) |
A single share of LENZ Therapeutics represents a small ownership stake in the entity. As a stockholder of LENZ, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
LENZ Therapeutics Dividends Analysis For Valuation
Please note that LENZ Therapeutics has scaled down on payment of dividends at this time. Price Earnings To Growth Ratio is likely to rise to 0.14 in 2026, despite the fact that Retained Earnings are likely to grow to (124 M).
There are various types of dividends LENZ Therapeutics can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of LENZ shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from LENZ Therapeutics directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When LENZ pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of LENZ Therapeutics by the value of the dividends paid out.
LENZ Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of LENZ Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value LENZ we look at many different elements of the entity such as LENZ's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as LENZ Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use LENZ Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes LENZ Therapeutics' worth.Additional Tools for LENZ Stock Analysis
When running LENZ Therapeutics' price analysis, check to measure LENZ Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LENZ Therapeutics is operating at the current time. Most of LENZ Therapeutics' value examination focuses on studying past and present price action to predict the probability of LENZ Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LENZ Therapeutics' price. Additionally, you may evaluate how the addition of LENZ Therapeutics to your portfolios can decrease your overall portfolio volatility.